Current pharmacotherapy options for cancer anorexia and cachexia (Q38052613)

27 August 2017

Current pharmacotherapy options for cancer anorexia and cachexia (English)

1 reference

27 August 2017

0 references

Antonio Macciò

1

1 reference

27 August 2017

Clelia Madeddu

series ordinal

2

1 reference

27 August 2017

Giovanni Mantovani

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

17 October 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

1 reference

27 August 2017

13

1 reference

27 August 2017

2453-2472

1 reference

27 August 2017

17

1 reference

The origins of cachexia in acute and chronic inflammatory diseases.

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Cachexia: a new definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Myostatin is a novel tumoral factor that induces cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Hypothalamic inflammation and energy homeostasis: resolving the paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Mechanisms of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Glucose-6-phosphate dehydrogenase--from oxidative stress to cellular functions and degenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Free radicals and antioxidants: updating a personal view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Cachexia and oxidative stress in cancer: an innovative therapeutic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Inflammation and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Anti-inflammatory therapies in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

More is better: a multimodality approach to cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Cancer cachexia: developing multimodal therapy for a multidimensional problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Definition and classification of cancer cachexia: an international consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Is there a role for parenteral nutrition or hydration at the end of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Nutritional support of the cancer patient: issues and dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Nutritional support in multimodal therapy for cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Medroxyprogesterone acetate in the management of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Managing cancer-related anorexia/cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Dangers of growth hormone therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

The role of the endocannabinoid system in eating disorders: pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Emergence of ghrelin as a treatment for cachexia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Branched-chain amino acids: the best compromise to achieve anabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Iron, infections, and anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Nutritional interventions for cancer-induced cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Mindfulness meditation for oncology patients: a discussion and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Turning toward dissonance: lessons from art, music, and literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

Addressing spirituality within the care of patients at the end of life: perspectives of patients with advanced cancer, oncologists, and oncology nurses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.734297

10.1517/14656566.2012.734297

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference